2-methyl-4,6-dimethylthio-5-nitropyrimidine | 138972-76-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-methyl-4,6-dimethylthio-5-nitropyrimidine
• 英文别名: 4,6-bis(methylthio)-2-methyl-5-nitropyrimidine；2-methyl-4,6-bis(methylthio)-5-nitropyrimidine；2-Methyl-4,6-bis(methylsulfanyl)-5-nitropyrimidine
• CAS: 138972-76-6
• 化学式: C₇H₉N₃O₂S₂
• 分子量: 231.299
• InChiKey: BHWQPIZGAODKJB-UHFFFAOYSA-N

物化性质

• 沸点：
  345.2±42.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  122
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-methyl-4,6-dimethylthio-5-nitropyrimidine 在 镍 氢气 、 N,N-二甲基苯胺 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 25.0~100.0 ℃ 、101.33 kPa 条件下， 反应 8.5h， 生成 1-Cycloheptyl-1-[4-(4-fluoro-phenoxy)-benzyl]-3-(2-methyl-4,6-bis-methylsulfanyl-pyrimidin-5-yl)-urea
  参考文献：
  名称：

  Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase. 3. Discovery of a Novel Series of N-Alkyl-N-[(fluorophenoxy)benzyl]-N‘-arylureas with Weak Toxicological Effects on Adrenal Glands

  摘要：

  A series of N-alkyl-N-[(fluorophenoxy)benzyl] -N'-arylureas were prepared and evaluated for their ability to inhibit intestinal acyl-CoA:cholesterol O-acyltransferase and to inhibit accumulation of cholesteryl esters in macrophages in vitro. In vivo hypocholesterolemic activity was assessed in cholesterol-fed rats by oral administration as a dietary admixture and/or by gavage in a PEG400 vehicle. Modification of the alkyl substituent on the N'-aryl moiety and on the urea nitrogen significantly influenced macrophage assay in vitro. Toxicological study revealed a distinct relationship between macrophage assay and the toxicity observed in adrenal glands of rabbits treated with representatives of this series of compounds. Investigations utilizing the macrophage assay as an indicator for adrenal toxicity led to the identification of compounds 1g (FR190809) and 1k (FR186485, or FR195249 as its hydrochloride salt) as potent, nonadrenotoxic, orally efficacious ACAT inhibitors irrespective of the administration method.

  DOI：

  10.1021/jm980399q
• 作为产物：
  描述：

  2-甲基-4,6-二氯-5-硝基嘧啶 、 sodium thiomethoxide 以 甲醇 为溶剂， 反应 1.0h， 以55%的产率得到2-methyl-4,6-dimethylthio-5-nitropyrimidine
  参考文献：
  名称：

  Amide compounds and medications containing the same technical field

  摘要：

  本发明提供了一种具有ACAT抑制活性的新型化合物。本发明涉及由式(I)表示的化合物，其中表示一个可选择取代的二价残基，如苯、吡啶、环己烷或萘，或一个基团，Het表示一个含有来自氮原子、氧原子和硫原子的异原子中至少一个的5-至8-成员取代或未取代的杂环基，例如单环基、多环基或融合环的基团，X表示—NH—、一个氧原子或一个硫原子，Y表示—NR4—、一个氧原子、一个硫原子、一个亚氧化物或一个砜，Z表示一个单键或—NR5—，R4表示氢原子、低碳基团、芳基或一个可选择取代的硅基低碳基团，R5表示氢原子、低碳基团、芳基或一个可选择取代的硅基低碳基团，n为1至15的整数，或其盐或溶剂合物，以及含有这些化合物之一的药物组合物。

  公开号：

  US06849647B1

文献信息

• Amide compounds and medications containing the same technical field
  申请人：Shibuya Kimiyuki

  公开号：US06849647B1

  公开（公告）日：2005-02-01

  The present invention provides to a novel compound having an ACAT inhibiting activity. The present invention relates to compounds represented by formula (I) wherein represents an optionally substituted divalent residue such as benzene, pyridine, cyclohexane or naphthalene, or a group, Het represents a 5- to 8-membered, substituted or unsubstituted heterocyclic group containing at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, such as a monocyclic group, a polycyclic group or a group of a fused ring, X represents —NH—, an oxygen atom or a sulfur atom, Y represents —NR 4 —, an oxygen atom, a sulfur atom, a sulfoxide or a sulfone, Z represents a single bond or —NR 5 —, R 4 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, R 5 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, and n is integer of from 1 to 15, or salts or solvates thereof, and a pharmaceutical composition containing at one of these compounds.

  本发明提供了一种具有ACAT抑制活性的新型化合物。本发明涉及由式(I)表示的化合物，其中表示一个可选择取代的二价残基，如苯、吡啶、环己烷或萘，或一个基团，Het表示一个含有来自氮原子、氧原子和硫原子的异原子中至少一个的5-至8-成员取代或未取代的杂环基，例如单环基、多环基或融合环的基团，X表示—NH—、一个氧原子或一个硫原子，Y表示—NR4—、一个氧原子、一个硫原子、一个亚氧化物或一个砜，Z表示一个单键或—NR5—，R4表示氢原子、低碳基团、芳基或一个可选择取代的硅基低碳基团，R5表示氢原子、低碳基团、芳基或一个可选择取代的硅基低碳基团，n为1至15的整数，或其盐或溶剂合物，以及含有这些化合物之一的药物组合物。
• Novel cyclic diamine compounds and medicine containing the same
  申请人：Kowa Company, Ltd.

  公开号：US20040038987A1

  公开（公告）日：2004-02-26

  The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same. The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. 1 (In the formula, 2 is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group where Ar is an optionally substituted aryl group; X is —NH—, oxygen atom or sulfur atom; Y is —NR 1 —, oxygen atom, sulfur atom, sulfoxide or sulfone; Z is a single bond or —NR 2 —; R 1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; R 2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; l is an integer of from 0 to 15; m is an integer of 2 or 3; and n is an integer of from 0 to 3). The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).

  本发明提供了新颖的环状二胺化合物以及含有该化合物的药物组合物。本发明涉及由式(I)表示的化合物或其盐或溶剂化合物。(在该式中，2是苯、吡啶、环己烷或萘的可选择取代的二价残基，或者是Ar为可选择取代芳基的乙烯基；X为—NH—、氧原子或硫原子；Y为—NR1—、氧原子、硫原子、亚砜或砜；Z为单键或—NR2—；R1为氢原子、可选择取代的较低烷基、可选择取代的芳基或可选择取代的硅烷较低烷基；R2为氢原子、可选择取代的较低烷基、可选择取代的芳基或可选择取代的硅烷较低烷基；l为0到15的整数；m为2或3的整数；n为0到3的整数)。本发明的化合物可用作药物组合物，特别是作为酰辅酶A胆固醇酰基转移酶(ACAT)的抑制剂。
• Novel amide compounds and medications containing the same
  申请人：Shibuya Kimiyuki

  公开号：US20050131002A1

  公开（公告）日：2005-06-16

  The present invention provides to a novel compound having an ACAT inhibiting activity. The present invention relates to compounds represented by formula (I) wherein represents an optionally substituted divalent residue such as benzene, pyridine, cyclohexane or naphthalene, or a group, Het represents a 5- to 8-membered, substituted or unsubstituted heterocyclic group containing at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, such as a monocyclic group, a polycyclic group or a group of a fused ring, X represents —NH—, an oxygen atom or a sulfur atom, Y represents —NR 4 —, an oxygen atom, a sulfur atom, a sulfoxide or a sulfone, Z represents a single bond or —NR 5 —, R 4 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, R 5 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, and n is an integer of from 1 to 15, or salts or solvates thereof, and a pharmaceutical composition containing at least one of these compounds.

  本发明提供了一种具有ACAT抑制活性的新化合物。本发明涉及由式(I)表示的化合物，其中表示一种可选取代的二价残基，例如苯，吡啶，环己烷或萘，或者一个基团，Het表示一种5-至8-成员的取代或未取代的杂环基团，其中至少包含从氮原子，氧原子和硫原子中选取的一种杂原子，例如单环基团，多环基团或融合环的基团，X表示-NH-，氧原子或硫原子，Y表示-NR4-，氧原子，硫原子，亚砜或磺酰基，Z表示单键或-NR5-，R4表示氢原子，低碳基，芳基或可选取代的硅烷低碳基，R5表示氢原子，低碳基，芳基或可选取代的硅烷低碳基，n为1到15的整数，或其盐或溶剂，以及含有这些化合物中至少一种的药物组合物。
• Novel amide compounds and medications containing the same technical field
  申请人：Shibuya Kimiyuki

  公开号：US20050131001A1

  公开（公告）日：2005-06-16

  The present invention provides to a novel compound having an ACAT inhibiting activity. The present invention relates to compounds represented by formula (I) wherein represents an optionally substituted divalent residue such as benzene, pyridine, cyclohexane or naphthalene, or a group, Het represents a 5- to 8-membered, substituted or unsubstituted heterocyclic group containing at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, such as a monocyclic group, a polycyclic group or a group of a fused ring, X represents —NH—, an oxygen atom or a sulfur atom, Y represents —NR 4 —, an oxygen atom, a sulfur atom, a sulfoxide or a sulfone, Z represents a single bond or —NR 5 —, R 4 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, R 5 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, and n is an integer of from 1 to 15, or salts or solvates thereof, and a pharmaceutical composition containing at least one of these compounds.

  本发明提供了一种具有ACAT抑制活性的新化合物。本发明涉及由式(I)表示的化合物，其中表示可选取代的二价残基，例如苯，吡啶，环己烷或萘，或基团，Het表示包含至少一种异原子（从氮原子，氧原子和硫原子中选择）的5-至8-成员取代或未取代的杂环基团，例如单环基团，多环基团或融合环基团，X表示-NH-，氧原子或硫原子，Y表示-NR4-，氧原子，硫原子，亚砜或磺酰基，Z表示单键或-NR5-，R4表示氢原子，低碳基，芳基或可选取代的硅基低碳基，R5表示氢原子，低碳基，芳基或可选取代的硅基低碳基，n为1至15的整数，或其盐或溶剂，以及含有这些化合物中至少一种的药物组合物。
• Pyrimidine derivatives and pharmaceutical compostions containing them
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP0561175A1

  公开（公告）日：1993-09-22

  The present invention relates to novel 5-(ω-substituted amino-alkanoyl amino)pyrimidine derivatives, processes for producing the derivatives, and pharmaceutical compositions containing said derivatives. The compounds of the present invention have potent effects of inhibiting ACAT activity and lowering serum cholesterol. The compounds of the present invention are extremely useful for the treatment and/or prevention of arteriosclerosis or hyperlipidemia.

  本发明涉及新型 5-(ω-取代氨基-烷酰氨基)嘧啶衍生物、生产该衍生物的工艺以及含有上述衍生物的药物组合物。 本发明的化合物具有抑制 ACAT 活性和降低血清胆固醇的强效作用。本发明的化合物对于治疗和/或预防动脉硬化或高脂血症非常有用。